Tumour and serum KRAS2 mutation and carcinoembryonic antigen (CEA) status in group A and controls
| All | TVA | Dukes’ A | Dukes’ B | Dukes’ C | Dukes’ D | |
|---|---|---|---|---|---|---|
| *41 patients were tumour KRAS2 mutation positive, one patient with Dukes’ A disease had both a codon 12 and codon 13 mutation. | ||||||
| †1 patient had a serum mutant KRAS2 detectable preoperatively that was not detected in the primary tumour, possibly a result of tumour heterogeneity and sampling error. | ||||||
| ‡In tumour KRAS2 mutation positive cases, there was a non-significant increasing prevalence of serum mutant KRAS2 positivity with advancing disease stage (p=0.308, Fisher’s exact test). | ||||||
| TVA, tubulovillous adenoma; CRC, colorectal carcinoma. | ||||||
| CRC cases | 78 | 9 | 7 | 30 | 21 | 11 |
| Tumour KRAS2 mutation positive | 41 (53)* | 7 (78) | 3 (43)* | 16 (53) | 7 (33) | 8 (73) |
| Codon 12 | 32 | 6 | 2 | 14 | 6 | 4 |
| Codon 13 | 10* | 1 | 2* | 2 | 1 | 4 |
| Serum KRAS2 mutation positive | 32 (41)† | 4 (44) | 2 (29) | 12 (40)† | 6 (29) | 8 (73) |
| Tumour KRAS2 and serum KRAS2 mutation positive‡ | 31/41 (76) | 4/7 (57) | 2/3 (67) | 11/16 (69) | 6/7 (86) | 8/8 (100) |
| CEA positive (>5 ng/ml) | 29 (37) | 2 (22) | 2 (29) | 11 (36) | 9 (43) | 5 (45) |
| Normal controls (n=20) | ||||||
| Serum mutation positive | 0 | |||||